Therefore, we conducted additional analysis using a “new-user design” that required patients who did not have a history of cancer to be free of any studied insulin use during the 6-month period preceding the start of insulin treatment and censored patients when they stopped using glargine insulin or intermediate/long-acting HI or started using another study insulin [17]. This evidence concerns the gene INS and cancer.